Talk:Somatic evolution in cancer

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine
Mid	This article has been rated as Mid-importance on the project's importance scale.

Tip: Anchors are case-sensitive in most browsers.

This article contains broken links to one or more target anchors:

[[Lung cancer#Non-small cell lung cancer|non-small cell lung cancer]] Anchor Lung cancer#Non-small cell lung cancer links to a specific web page: Non-small-cell lung cancer. The anchor (#Non-small cell lung cancer) is no longer available because it was deleted by a user before.

The anchors may have been removed, renamed, or are no longer valid. Please fix them by following the link above, checking the page history of the target pages, or updating the links.

Remove this template after the problem is fixed | Report an error

The

The initial version of this page was written by members of the Santa Fe Institute working group on integrating evolutionary theory into cancer biology, including Carlo Maley, Brian Reid, John Pepper, Sabrina Spencer, Henry Heng and Tom Vincent.

There are some parts that could use some fleshing out:

Multilevel selection
Epigenetics
Phylogenetic analyses
Other forms of therapeutic resistance where the resistance has been caused by a known genetic or epigenetic (heritable) mechanism:
- Methotrexate
- Mutations and amplication of AR in anti-androgen therapy for prostate cancer
Add links to other wikipedia pages (e.g., Gefitinib? 5-flurouracil?)
Glossary

Carlo Maley (talk) 22:59, 16 July 2008 (UTC)[reply]